Literature DB >> 29072978

Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?

Andrew Berchuck1, Angeles Alvarez Secord1, Haley A Moss1, Laura J Havrilesky1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29072978     DOI： 10.1200/JCO.2017.74.5752

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.

Authors:  Joseph A Dottino; Haley A Moss; Karen H Lu; Angeles A Secord; Laura J Havrilesky
Journal:  Obstet Gynecol       Date:  2019-04       Impact factor: 7.661

2.  Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing.

Authors:  Shelly Cummings; Susana San Roman; Jennifer Saam; Ryan Bernhisel; Krystal Brown; Johnathan M Lancaster; Lydia Usha
Journal:  J Ovarian Res       Date:  2021-04-29       Impact factor: 4.234

3.  Understanding the needs and perspectives of ovarian cancer patients when considering PARP inhibitor maintenance therapy: Findings from two online community events.

Authors:  Karen A Monuszko; Laura J Fish; Dorinda Sparacio; Christina Lizaso; Kathryn Burn; Natalie E Wickenheisser; Larissa A Meyer; Shelby D Reed; Brittany A Davidson; Laura J Havrilesky
Journal:  Gynecol Oncol Rep       Date:  2022-07-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.